

Bio-Entrepreneurship



Pankaj Sharma CEO & Cofounder

- 1. Who am I
- 2. What I do
- **3. Building biotech business key learning**







Spun out from IIT D 2007 Incubated on campus 2007 - 2010 Focus: Drug discovery



BioSpectrum Asia conference & Annual Industry awards 2011

16th March, Singapore

A distinctive honor...

BioSpectrum

Awards

2013





LeadInvent molecule to fight latent TB

BALL 2011



riter, 1000 transation officer, of Localitane (1

rulating capital by constructing the govermont' agencies to fland projecta with no truck perced, Secondly, we fazed the barrier of interacting with the scientific community who had done drug discovery with tatellastual property (IP) strategists. Hence out doullenge will, how to place and structure LeadEntent as an IP rich and IP subgranded company '

Overcoming the challenges, Load levent managed to term little over \$30,000 (Cia lakh) of sted funding

BioSpectrum Asia Pacific Emerging **Company of the Year** Pankai Sharma Chief Executive Officer, LeadInvent Inclin







What we do







Background





Building biotech business – key learning



Easy to start Challenging to grow

Keep in mind the

"Indian context"





- Identify pain point
- •Who's going to pay for it
- Competition & IP landscaping
- Validate technology Feedback
- Micro Vision
 &
 Macro Vision
- •Funding



Building up





© SaipFund





Remember what JFK did





Thanks



Pankaj: pankaj@leadinvent.com

Mob: 91-9910122566

Status:

© LeadInvent. all rights reserved





SENSITIZATION WORKSHOP ON

"INTELLECTUAL PROPERTY, TECHNOLOGY MANAGEMENT & ENTREPRENEURSHIP"

11" January, 2013

Organised by

Biotechnology Industry Research Assistance Council

A Government of India Enterprise, New Delhi (www.birac.nic.in)

at

Shri Mata Vaishno Devi University, Katra, Jammu, J&K

" BIRAC Initiatives for Nurturing Entrepreneurship"

11th Janurary 2013, Jaipur

Mr. RUTURAJ PATIL MSc(Biotech), MIBM(London) Manager- Business Development & Corporate Affairs, BIRAC



Copyright @ BIRAC 2013

The Need-Innovation to Commercialization



Entrepreneurship Development



Copyright @ BIRAC 2013

Nurturing Entrepreneurship

1. Entrepreneurial motivation: the social and economic importance of commercialising science and technology; the innovative aspects of it; education & training, role models, examples and discussions.

2. **Opportunity recognition**: this is a very important aspect of entrepreneurship, one needs to "identify" an opportunity that motivates them to pursue it. Opportunities at research and commercial levels.

3. **Commercialisation:** through a variety of methods of technology transfer to different levels of product development. Lectures from practitioners; business plan competitions; short pieces of course work; small group supervisions etc.



Framework For Necessary Factors For Enterprise Development





Government: DBT-BIRAC's Role

- Linking Education, Innovation and Entrepreneurship 'Connector and Catalyser'
- Biotech Incubation for Entrepreneurship (BISS Scheme)
- Education and Training Support activities to Start-ups & SME's in Biotech
- Fostering Innovation and Enterprises Building
- Awareness and Capacity Building for new budding Entrepreneurs
- Fellowship/Internship programmes
- Mentorship and Networking Events



BIRAC Initiative:

- Supporting Public Private Partnership in Biotechnology research
- Fostering Innovation & Research in Biotechnology
- Promoting Entrepreneur Education & Learning
- Empowering & Mentoring SME's
- Innovators Awards for successful entrepreneurs
- Growth through Regional Partnerships
- International Collaborations



BIRAC Support for taking discovery to product development

Commercial Scale-up

Technology Transfer

Application Development

Application Identification

Technology Development

BIG

Proof of Concept

New Ideas

BISS Scheme

BIPF

Preduct

Development

Incubation Support



Copyright @ BIRAC 2013

SBIRI

Biotechnology Ignition Grant (BIG) Scheme

Purpose:

Establish and validate of Proof of Concept

Encourage researchers to take technology closer to market through a Start Up **Target Groups:**

Entrepreneurs from Academia or an Incubatee

(PhDs, Medical degree holders or M.Tech, Engg. Graduates)

Support:

Grant-in-Aid limited up-to INR 50 Lakh

Mentoring and hand-holding

Supports up-to Proof-of-Concept stage

Copyright @ BIRAC 2013

Small Business Innovation Research Initiative- SBIRI

Purpose:

•Govt. partnership with Industries

• For path-breaking research in frontier futuristic technology areas having major economic potential.

Focused on IP creation

• IP ownership retained by Indian industry/collaborating scientists.

Target:

 Indian Biotech companies registered under Indian Company Act 1956

Support:

• To nurture high risk, highly innovative accelerated technologies/entrepreneurs

• Support early stage, proof-of-concept research

Over 100 projects from SME's supported

SBIRI deployed \$36million of which US\$5million was in grant & US\$31million as soft loan

Biotechnology Industry Partnership Programme- BIPP

Purpose:

- •Govt. partnership with Industries
- Cost sharing basis
- For path-breaking research in frontier futuristic technology areas having major economic potential.
- Focused on IP creation
- IP ownership retained by Indian industry/collaborating scientists.

Support:

For high risk, highly innovative accelerated technology

•For nationally and socially relevant areas, with no assured market.

• Supporting research project for novel IP generation.

Target:

 Indian Biotech companies registered under Indian Company Act 1956

•51% Indian shareholding (including NRI's)

DSIR recognized R&D

• Apply independently or in collaboration with companies, not for Profit organisation or academics partners

Nearly 100 agreements have been signed with 85 companies with approx. 50 SME's

Investment of US \$153million has been committed with US\$55 million by Govt. of India with contribution of US\$98 million coming in from private sector.

Contract Research Scheme- CRS

Purpose:

Academia-industry interaction Industry to validate process or partner for specific research

Leads should be at a level which provides sufficient data for Scale up/Validation:

• Exploratory validation of technology

• Small scale contract research resulting in generating several batches of process or multiple prototypes

 Large scale validation of prototype to commercial design

Target Groups-

Research institutes, Universities, Public funded research Laboratories, Governmental organizations, Research foundations AND Companies / industries

Company partner should have DSIR recognized R&D/Service unit(s)

Support:

•Funds for validation of PoC

•IP Services and Management

 Legal support: MTA, NDA, IP protection contracts, Licensing agreements

Bio-incubator Support Scheme- BISS

Purpose:

Strengthening and Up-gradation of the existing Bio-incubators and also to establish New World Class Bio-incubators in certain strategic locations.

Target Groups:

Existing Bio-incubators across the country
New Bioincubators

Support:

• Provide incubator space to Start-ups and Entrepreneurs.

- Provide access to a pool of special equipments in the Central Equipment Facility.
- Connect and facilitate Industry Academia Interaction
- Provide enabling services and required mentorship for IP and Technology Management, Legal and Contract, resource mobilization and networking platform.
- Governance models would be cooperative or autonomous.
- •12 existing Bio-incubator across India has been supported approx. 70,000 sq.ft Bio-Incubator has been created.

Identifying Key Gaps

- Entrepreneurship Development is complex process need to find proper mechanism as per local resources availability
- Enabling Capacity building and Handholding services
- Fostering and encouraging techno- Entrepreneurship in all places research.
- Provide Mentorship & Faculty development programmes.



Strategic Partners

- **Global Partners-** Centre for Entrepreneurship Education at Cambridge University, WHO, Gates Foundation, PATH, etc
- Launching **IGNITE** Programme in July 2013.
- National Partners- DBT & Allied Institutes, ICMR, IIT's, Leading Medical & Technological University & Institutions, DBT-BIRAC Supported Bio-Incubators, ISBA, ABLE, BCIL



THANK YOU



Copyright @ BIRAC 2013



Biotechnology Industry Research Assistance Council

Website- <u>www.birac.nic.in</u> Email- <u>rpatil.birac@nic.in</u>

"Technology Licensing in Drugs and Bio-Pharmaceuticals"



SHRI MATA VAISHNO DEVI UNIVERSITY, JAMMU

by

Dr. Goutam Bhattacharyya

© K&S Partners, Gurgaon

TECHNOLOGY

Complete set of Industrially

applicable knowledge

- Intellectual Asset
- Intellectual Property

What is Licensing

The granting of permission to use a bunch of RIGHTS/ ASSETS under

defined conditions.

Underlying principle of Licensing

- is basically about getting the fear and greed levels balanced between both parties.....
- Licensor's fear: cannot off-load the technology.
- Licensee fears: competitor will buy it and blow them out of the water.



as much as possible vs. as little as possible

all these sorted out = licence agreement
SYNC OF TWO MINDS

- Under estimation vs. Over estimation
- What industry (licencee) wants?
- Techno-economical viability of research?
- Most importantly mutual trust.

WHAT IS TECHNOLOGY LICENSING AND TRANSFER

Is a process by which a developer of technology makes its technology available to a commercial partner that will exploit the technology with defined conditions.

Reasons of licensing and transfer:

- Forming alliances with partners that can progress the development of the technology
 - Limitations of developer (up to animal studies not up to clinical and commercial phase).
- Forming alliances with partners with manufacturing capability (start up companies/ Universities).
- No commercial capability.

PRINCIPLES OF TECHNOLOGY LICENSING AND TRANSFER

Legal agreements are entered into by which:

- the right to exploit the technology is granted
- Compensation against those rights, and
- Setting out respective rights and duties

KINDS OF AGREEMENTS

- Agreement for showing interest
- Confidentiality Agreement
- Material transfer agreement
- Deed of Assignment
- License Agreement
- Strategic alliance or joint venture
 - Co-development agreement
 - Co-marketing agreement

CONFIDENTIAL AGREEMENT

legally binding agreement between a discloser of confidential information, and a recipient of confidential information on a defined terms and condition.

- Not known to others but have unique value,
- patentable/ trade-secret,
- for evaluation or testing purposes

MATERIAL TRANSFER AGREEMENT

- The material (vector, proteins) that embodies intellectual property, and that intellectual property needs to be protected.
 - recipient will not part with possession of the material, nor any progeny or derivatives, without the prior written consent of the provider of the material,
 - Defined use,
 - Safety,
 - Ethical issues.

ASSIGNMENT VS. LICENSING IN PHARMA SECTOR

incidence of assignment is significantly smaller than licensing.

-reduced financial upside

-inefficient financial terms

– no performance obligations

SUBJECT MATTER OF LICENCE

- granted patents
- PCT and provisional patent applications
- inventions, discoveries and other technical information that are not yet the subject of a patent application
- trade secrets and confidential information that are intended to remain as such.

TANGIBLE THINGS TO BE PROVIDED

- the original patent grants
- the original patent applications/ specifications
- laboratory notebooks
- biological materials: cell lines, vectors, compounds..
- the documents that demonstrate the chain of title of the intellectual property, for example, from employee to employer, from independent contractor to customer, from collaborator to joint owner, etc.

WARRANTY

- owner owns the IP
- that the commercialization of the IP will not infringe the rights of a third party <u>to the</u> <u>best of the owner's knowledge</u>
- that the intellectual property is not already licensed, nor subject to any agreement or option entered into by the owner
- that the intellectual property has not been encumbered by the owner in any way.

LICENCE AGREEMENT

- Underlying principle of licensing is "EXCLUSIVITY"
- Based on the exclusivity, Licences are of:
 - exclusive licences,
 - Sole licences,
 - Non-exclusive licences,
 - Patent pooling: collection of patents, owned by different entities, required to offer a product or service.

Types of licence agreements

- Unilateral licensing typically upfront payment and royalties from sales of product
- Cross-licensing involve an exchange between two or more patent portfolio and used for mutual use of patents by multiple patent holders.

COMPULSORY LICENCE

Compulsory licence in a patent

system in an involuntary contract

between willing buyer and unwilling

seller.

COMPULSORY LICENCE (CL)

Section 84:

At any time after the expiration of three years from the date of the [grant] of a patent, any person interested may make an application to the Controller for grant of compulsory licence on patent on any of the following grounds,

Namely: to be continued

GROUNDS FOR CL

- (a) that the <u>reasonable requirements</u> of the public with respect to the patented invention have not been satisfied, or
- (b) that the patented invention is not <u>available</u> to the public at a reasonably affordable price, or
- (c) that the patented invention is not worked in the territory of India."

APPLICATION FOR CL

- Negotiate with the patent holder
- If negotiation fails, approach Controller
- Controller will hear both the parties

– May or may not grant CL

-On a reasonable terms and conditions

BAYER CORPORATION VS. NATCO PHARMA

CONTROLLER GENERAL'S ORDER

CG found that all the 3 criteria above were satisfied in this case, namely:

a.that since Bayer supplied the drug to only <u>2% of the</u> <u>patient population</u>, the reasonable requirements of the public with respect to the patented drug (Nexavar) were not met.

b.that Bayers pricing of the drug (2.8 lakhs for a months' supply of the drug) was excessive and did not constitute a "reasonably affordable" price.

c.that Bayer did not sufficiently <u>work</u> the patent in India.

MAXIMIZING THE BENEFITS: FIELD

• Licenses can be limited to a particular

area of application,

- human applications
 - diagnostic
 - therapeutic vaccines
 - prophylactic vaccines.
- plant applications
- veterinary applications.

MAXIMIZING THE BENEFITS: TERITOREAL

- Global licensing,
- Limited geographical area,
 - exclusive license for North America
 - yet grant an exclusive license of the same
 intellectual property to another licensee for the
 territory of Europe,
 - and yet another for the territory of Asia.

MAXIMIZING THE VALUE

- Part licensing
- License remaining parts to other companies.
- While licensing one should aim at long term relationship with the licensee
- There would always be conflict of interests but that has to be managed.

IMMENSE POTENTIAL

- USA- Patent licensing revenue
 - \$15 billion in 1990
 - \$ 100 billion in 1998.
 - Expected to grow to half trillion by the middle of next decade.
- Japan- earned JPY 340 billion in 2002
 - spent JPY 210 billion on obtaining license.
- France- earned EUR 330 million (1990) to EUR 2.4 billion (2003).

DUE DILIGENCE IN LICENSING

- Identify IPR at issue
- Look at company's IP files
- Search IP held by the company in databases
- Review corporate files
- Review key products

DUE DILIGENCE IN LICENSING

- Review business records
- Interview persons familiar with development to identify trade

secrets, unregistered trade marks

• Determine ownership of IP

Some anti-competitive practices

- Grant-back licensing licensee must license back to licensor any improvement patent
- Tie-in-clause licensee is forced to purchase un-patented material (e.g., raw materials)
- Package licensing- licensor forcibly licenses undesired IPR along with patents (trademark)
- Condition prohibiting a licensee from challenging the validity of licensor's IPR

Licensing Strategies



Projected Pharmaceutical Industry Growth by Strategic Activity



TOP INTERNATIONAL LICENSING DEAL IN 2012



DEAL SIZE:

Bristol-Myers Squibb - AstraZeneca

Licensor: Bristol-Myers Squibb Licensee: AstraZeneca Deal size: \$3.5 billion

More than five years ago BMS and AZ tie knot over their R&D and commercialization collaboration focused on Type 2 diabetes drugs:

- Onglyza (saxagliptin; DPP-4 inhibitor);
- Kombiglyze (saxagliptin and metfomin HCI extended-release)
- Forxiga (dapagliflozin; SGLT2 inhibitor).

BMS's purchases <u>Amylin</u> for **\$7** billion

BMS licenses its diabetes portfolio to Astra for \$3.5 billion

Astra and BMS Contd...

- Amylin's portfolio for diabetes, includes:
 - The GLP-1 agonists,
 - Byetta (exenatide) injection and
 - Bydureon (exenatide extended-release)
 - delivery devices and formulation improvements;
 - Metreleptin, a leptin analog currently under review by FDA to treat diabetes and/or hypertriglyceridemia in patients with lipodystrophy;
 - Symlin (pramlintide acetate) injection an amylin analog, FDA approved

TOP 20 LICENSING DEALS OF 2012

S.NO.	LICENSOR	LICENSEE	SIZE OF THE DEAL (\$)	AREA OF TECHNOLOGY
1.	Bristol-Myers Squibb	AstraZeneca	3.5 bn	Diabetes
2.	Galapagos NV	Abbott Laboratories	1.35 bn	Autoimmune diseases
3.	Endocyte	Merck	1.0 bn	Late stage ovarian cancer
4.	Forma Therapeutics	Boehringer Ingelheim	815 m	Multiple oncology targets
5.	Forma Therapeutics	Janssen (Johnson & Johnson)	700 m	Tumour metabolism
6.	<u>Xenon</u>	Genentech	646 m	Pain medication
7.	Threshold Pharmaceuticals	Merck KGaA	550 m	Cancer
8.	Celgene	Inhibrx	500 m	Antibody
9.	Thrombogenics	Merck KGaA	490 m	Symptomatic vitreomacular adhesion (eyes)
10.	<u>Enanta</u>	Novartis	440 m	Hepatitis C
11.	AC Immune	Genentech	418 m	Alzheimers
12.	Bionomics	Ironwood Pharmaceuticals	345 m	Anxiety disorders
13.	Virobay	Leo Pharma	307 m	Dermatology
14.	Angiochem	GlaxoSmithKline	300 m	CNS disorders
15.	Isis Pharmaceuticals	Biogen Idec	299 m	Spinal muscular atrophy
16.	Isis Pharmaceuticals	Biogen Idec	271 m	Myotonic dystrophy
17.	FivePrime Therapeutics	GlaxoSmithKline	223.5 m	Asthma and chronic obstructive pulmonary disease
18.	BioDelivery Sciences	Endo Pharmaceuticals	180 m	Pain medication
19.	<u>Genmab</u>	Novartis	175 m	Antibodies
20.	Mannkind Corp.	Tolero Pharmaceuticals	130 m	Hemtological malignancies and inflammatory diseases

PFIZER

 In terms of overall commercial success of licensed products, Pfizer is by far the leader with total revenues of \$15.1bn in 2002 from licensed products.

OUR OWN CSIR

Natural Streptokinase by CSIR-IMTECH licensed to Cadila and is already available in the Indian market under the STpase brand name.

Recombinant STpase roughly ten times as efficient as a natural SK.

This technological package was licensed to M/S Shasun Chemicals & Drug Ltd., Chennai, from 2002-2003.

This product was launched in the Indian markets in July 2009 under the brand names "Lupiflo" and "Klotbuster".

IN A NUTSHELL....

- Identify the need (e.g.)
- Proper due diligence of the partners
- Avoid being demanding
- Mutual trust is the key
THANK YOU

goutam@knspartners.com +91-9810357500

PATENT SEARCH



Sensitization Workshop on Intellectual Property Technology Management and Entrepreneurship

> on 11th January 2013 at Shri Mata Vaishno Devi University

> > Sibi Sagar <u>ssagar.birac@nic.in</u>

Importance of Patent Search

- Learning more about a new field
- For market information
- Competitor tracking
- Technology tracking
- Inventive thinking by challenging the inventors with the novelty of the idea
- Critical step before filing a patent application



Patent Search Types

- State-of-the-art Searches
- Novelty/Patentability Searches
- FTO/Infringement/Clearance Searches
- Validity/Invalidity Searches



State-of-the-art Searches

- 4
- To find out what technology already exists and then build on it.
- Provides up-to-date information about progress in a specific technical field
- Results can identify new areas for investment, research and development, or acquisition
- Search Patent as well as Non-Patent Literature



Novelty/ Patentability Searches

- An inventor has an invention which he is interested in patenting
- To determine if anyone has previously invented anything similar or identical
- Determine Whether to Pursue Patent Protection
- To better define the inventive contribution of the new product over the prior art
- Use Search Results to Strengthen Patent Application
- Pre-empt the Examiner's Prior Art Rejections



Novelty/ Patentability Searches (contd..)

- Patentability Search is NOT an Infringement Search
- Prior Art to be Searched
 - Patent Published, Application and Non-Patent Literature
 - Published anywhere in the world
 - No Date constraints
 - Evidence of past public use or sale
- Search not a legal requirement
- Anything disclosed to public, in any manner, at any time, cannot be patented.



FTO/Infringement/Clearance Searches

- To demonstrate that a proposed product does not infringe any in-force patents
- □ If infringement exists, take appropriate business decision

Search Scope

- exclude expired patents, Limit date range to the last 20 years
- exclude Non-patent literature
- Is Jurisdiction specific
- Claims
- It is the Claims which determine what it would take to infringe that patent
- In-force claims may be very broad and not include all features of the proposed product or invention.
- E.g. the new product may include A + B + C + D This combination will infringe an earlier and broader claim that only recites A + B.



Validity/Invalidity Searches

Patent Office may have issued the patent in error.

- A company has made a product that infringes upon another company's patent and are being sued.
- Exhaustive Prior Art Search conducted after patent issuance
- To validate the enforceability of a patent's claims or to invalidate one or more claims of a patent
- A successful Validity search finds references that the Patent Office missed.



Validity/Invalidity Searches (contd..)

- The grounds to invalidate a patent differ according to the national patent laws of different countries
 - Publication of the invention prior to the priority date of the application for patent,
 - Sales of the invention,
 - Prior public knowledge, or prior public use.

Search

- Prior art patents or non-patent publications
- Date prior to filing date of invention of the target patent.



Patent Databases

Free Patent Databases

- United States Patent Trademark Office (USPTO) <u>http://patft.uspto.gov/</u>
- EPO-espacenet
- Patent Lens <u>www.patentlens.net</u>
- WIPO Patentscope

http://patentscope.wipo.int/search/en/search.jsf

- Google Patents
- Free Patent Online <u>www.freepatentsonline.com</u>
- Indian Patent Office <u>http://ipindiaservices.gov.in</u>

and many more....



United States Patent Trademark Office (USPTO)

11





Espacenet

<i>)</i>	Europāisches Patentamt European Patent Office Office europé des brevets

htamt ppean int office ce européen brevets **Espacenet** Patent search Deutsch English Français

Contact

Change country 💌

4 About Espacenet Other EPO o	nline services 🔻
Search Result list ★ M	ly patents list (0) Query history Settings Help
Smart search	Help
Quick search	Search
Advanced search	
Number search	Number searches
Classification search	
	If you have found a number (for example in an article or magazine) but you do not know what it represents (application, publication, priority or NPL reference number, for example) or which country it comes from, you can use the Number search or Smart search options to find the
Quick help –	relevant document.
 → Are the help files available in other languages? → How can I go back to the index list? 	All you have to do is enter the number in one of the search masks. Depending on availability, the result of your search may contain <u>bibliographic data</u> , a <u>description</u> , <u>claims</u> , <u>mosaics</u> , the <u>original document</u> (in facsimile mode), the <u>INPADOC legal status</u> and the <u>INPADOC patent family</u> . For more information on Espacenet, see the following pages:
	Index
	Application number
	Boolean operators
	<u>Country codes</u>
	Default operators
	Kind codes
	Limitations
	Publication number
	<u>Priority number</u>



Patent Lens

ens.net	습 ㅋ C 🔡 - Patent Lens
Patent Lens A free public resource for patent system navigation worldwide. An initiative of Cambia	Search this website
Home Patent Search & Tools Patent Landscapes Intellectual Property Medi	a Centre About I/s
Patent Lens is a worldwide, open-access, free full-text patent informatics resource. It serves as the cyberinfrastructure platform for the <u>Initiative for</u> Open Innovation (IOI). Why are we doing this?	Patent Lens New Features Patent search interface in Chinese (中文), English, Russian (Русский), and French.
Search Full-Text Patents	 Full text of PCT applications now searchable in Chinese, English, Frenc German, Japanese, Korean, Russian and Spanish Full text of EPO patents now searchable in English, French and German
Quick Search More Options Search and retrieve the full-text of over ten million patent documents from US, Europe, Australia and WIPO, their status and counterparts up to 70 countries.	 Search for lapsed, abandoned or expired US Patents. Visualize Patent Families with new graphical trees as PDFs. Patent Landscapes on Influenza Genes, Rice Genome and Adjuvants now online Protein & DNA Sequence searching of over 80 million sequences from worldwide patent collections.
	Selected Media
Search Sequences The Patent Lens Sequence Project allows you to search over 80 million DNA and protein sequences disclosed in patents. > Start searching sequences	Cambia is named to the list of World's Top 100 NGOs by The Global Journal The Global Journal, USA January 12, 2012 From the hundreds of thousands of Non-governmental organizations in the world, the Global Journal has selected the Top 100 based on impact, innovation, transparency, accountability and efficiency. Q&A with Richard Jefferson - Stanford Social Innovation Review Stanford Social Innovation Review, USA February 14, 2011 Richard Jefferson believes that biotechnology can be used to benefit the property of the S&D process is democraticed on

USPTO makes US faten Oata 20113available lante lante lante

that everyone has access to critical scientific tools and technologies.

Ignite Innevate Incubate

WWW?

WIPO Patentscope

Search Browse			
Detailed coverage info Front Page Any F	rmation can be found here (->)	cuments including 2,171,684 published ir nt. Classification(IPC) Names Da	nternational patent applications (PCT).
	PCT Honduras Argentina Israel Brazil Japan Chile Jordan Colombia Kenya Costa Rica Mexico Cuba Morocco Dominican Rep. Nicaragua Ecuador Panama El Salvador Peru Guatemala Republic of Korea	 Russian Federation Russian Federation (USSR data) Singapore South Africa Spain Uruguay Viet Nam ARIPO EPO LATIPAT a AII 	Examples: The entered value is searched against the Title, Abstract, Numbers and Names. 4 "electric car"~50 4 Smith or Klein 4 WO2010000001 4 EP2012001709 4 "sol* panel"~5 4 elect?icit? 4 electric^10 and car^3



Google Patents





Free Patent Online

k here for <u>syntax instructions</u> , field abbreviations and <u>character map</u> Image: Im	xpert Search	SEARCH BLOGS	MPEP 2.0 TOOLS & RES		DUCT & SERVICES	
Image: Date Range* All years Image: Date Range* On Image: Date Range* <td< th=""><th>k here for <u>syn</u></th><th>tax instructions, field abbreviation</th><th>ns and character map</th><th></th><th></th><th></th></td<>	k here for <u>syn</u>	tax instructions, field abbreviation	ns and character map			
Mon-patent Literature			 US Patent Applications EP documents Abstracts of Japan WIPO (PCT) German Patents (Beta) 	Word Stemming Sort Order	 On Chronological 	Relevancy
earch Reset	earch Res					

16



Indian Patent Office





Welcome to IPAIRS Version 2.0

Controller General of Patents Designs and Trademarks Department of Industrial Policy and Promotions Ministry of Commerce and Industry

Patent Search Engine Help

	Agent Register	Application Status	Published Applications	anted Patents
-		Granted Patents		
		Containing	ECTED 💽	NOT SEL
		Containing	ECTED	NOT SEL
		Containing	CTED	NOT SEL
		Containing	ECTED	NOT SEL
		Containing	CTED 💽	NOT SEL
	$\mathbf{}$	Containing	CTED	NOT SEL
	•	Containing	ECTED 💽	NOT SEL
		Containing	CTED	NOT SEL
	•	Containing	ECTED 💽	NOT SEL
		Containing	ECTED 💽	NOT SEL
		Containing	CTED 💽	NOT SEL
		Containing	ECTED 💽	NOT SEL
		Containing	CTED	NOT SEL



Patent Databases

Paid Patent Databases

- Thomson Innovation <u>www.thomsoninnovation.com</u>
- Delphion <u>www.delphion.com</u>
- Derwent World Patent Index
- STN <u>stnweb.cas.org</u>
- QPAT <u>www.qpat.com</u>

and many more..

Advantages: value added, better indexing, better search engine



Thomson Innovation

2MSEAN ININGVATION		ent Search					本語で表示 資体中文量示	1.6
NUMBER OF THE OWNER PORT				Quic	k Search: Patents	punter Go [*		
come Sanchita 🛛 🔞	Paten	t Search						2
Search	Fiek	led Search	Publication Nu	mber	Expert Search			
atient Search	Shire W. I	Create Slott	Edit Collections J D	Section & Vic	art Ontrons			
earth History arked List aved Searches & Alerts	O Hou				US App. FR App. WO App. DE UT Show Template			
Saved Work	C since	Text Fields		1	Show template	Show Operators		
Administration	-	Twee Fields	~					
My Account	AND	Title/Abstrac		1. 1.5	Dist Irring D	X		
Preferences	AND	Title Title-Origin	al and I foundably	8	Fillip	Ptowse X		
Support	AND .	Title-Origi	inal (English) Inal (French) Inal (German)	7 5	rom: 2008-01-01 To: 1000-000	Lool X		
	Clear Al		nai (Serman) inal (Spanish)					
	Make	Abstract-O	riginal Original (English)			Standa		
		Abstract-0	Original (French) Original (German)			A CONTRACTOR OF A CONTRACTOR OF		
		Claims	Original (Spanish)		-	Shirw Query Previewer 😒		_
		Claims (En Claims (Fre	anch)		Collections to Sear	ch 🛛 Chilert	ion Description Collection Sche	diile
	Claims (German) Claims (Spanish)			-	Enhanced Patent Data - D	WPI		
					Patent Collections by Auth	ority		
					Full Text			
					2 US Granted	[P] WIPO Applications	French Applications	
					US Applications	🛅 British Applications	German Utility Models	
					[2] European Granted	E Canadian Granted	📄 German Granted	
					12 European Applications	Canadian Applications	German Applications	
					Asian Translated			
					📰 Japanese Utility Models	📰 Korean Utility Models	📃 Chinese Utility Models	
					🗂 Japanese Granted	🗇 Korean Granted/Examined	Chinese Granted	
					🗐 Japanese Applications	🗐 Korean Applications	Chinese Applications	
					Bibliographic			
					per "Alterna Accessions".		Select All, F Cle	ALAR.
					V Also search DWPI fields for	selected collections		



Qpat

20

P Menu My Lists 兴	General search		
earch Patents 🔗	▲ Keywords		
Searches General search Number search Citation search	🖼 Title, Abstract, Key Content 🌱		E.g.,Telecom+ OR phone 🧐
Wy Session Search history Search results	Classifications A Names		
Trevious History	Assignee (Original or Currer		E.g.:Fleming Alexander, Moyer Andrew
Previous Intellixir Analysis My Searches My saved searches	Representative:		E.g.:Baker Botts 🥹
My alerts	 Numbers, Dates & Country 		
	Publ. number 👻	No restriction	E.g.:EP0980063 🥹
	Patents published in (Patent authorities):		E.g.:US, EP 🕖
	 → Legal status → More fields 		
		×	9
		Search Show the cmd, line Create script	Clear

STN

	ogon Query <u>R</u> esults	Setup Web H	<u>i</u> elp		
21 V8.4	son Logon	BLAST®			noup Custom Report Report Predefined Report Report Predefined Report Prefs Prefs Prefs Help Exit
	Transci	ipt Hig	hlights		
	=> FILE (CAPLUS		i.	
	=> S CHOO L2	COLATE 10189 CH		ATE OR CHOCOLATES)	Display record 1 to see the newest reference and record 10189 for the oldest reference in the answer set. Records in the answer set are in
	=> D 1, 10189				reverse chronological order.
	AU Husl CS Depa	rent even cins, Bra artment o nesaw, GA	nts into indon; Do of Chemis A, 30144, loator (2	the undergraduate teac ockery, Christopher R. stry and Biochemistry, USA 2009), 14(6), 236-238	n chocolate : incorporating hing laboratory Kennesaw State University,
	CODI PB Cher DT Jour	E <mark>N</mark> : CHEDF nical Edu	icator	Ch	e Full-text link takes you to
COMMON	CODI PB Cher DT Jour	SN: CHEDF nical Edu rnal; (on lish	DISPLAY FIELD	nputer file) 9 CAPLUS COPYRIGE ull-text	emPort [®] , which gives you options ailable for viewing the full text. The
RCH FIELD	CODI PB Cher DT Jour LA Eng CONTENT	EN: CHEDF nical Edu rnal; (on lish SEARCHFIELD CODE	DISPLAY FIELD	nputer file) ⁹ CAPLUS COPYRIGE ull-text opt	emPort [®] , which gives you options allable for viewing the full text. The tions range from publisher web sites
RCH FIELD	CODI PB Cher DT Jour LA Eng CONTENT	EN: CHEDF nical Edu cnal; (on lish SEARCHFIELD CODE	DISPLAY FIELD CODE	nputer file) ⁹ CAPLUS COPYRIGE ull-text opt	emPort [®] , which gives you options ailable for viewing the full text. The
RCH FIELD	CODI PB Cher DT Jour LA Eng CONTENT	EN: CHEDF nical Edu cnal; (on lish SEARCHFIELD CODE	DISPLAY FIELD	nputer file) 9 CAPLUS COPYRIGE ull-text storage, and ice-ma to a	emPort [®] , which gives you options allable for viewing the full text. The tions range from publisher web sites ordering the document.
ARCH FIELD	CODI PB Cher DT Jour LA Eng CONTENT Document title Author names Company or organization name	EN: CHEDF nical Edu cnal; (on lish SEARCHFIELD CODE	DISPLAY FIELD CODE TI AU	mputer file) 9 CAPLUS COPYRIGE ull-text storage, and ice-ma & Son, London). \$4.5	emPort [®] , which gives you options allable for viewing the full text. The tions range from publisher web sites ordering the document.
ARCH FIELD Ior Xorate roe	CODH PB Cher DT Jour LA Eng CONTENT Document title Author names Company or organization name tor author attiliation Publication year of the original	EN: CHEDF nical Edu cnal; (on lish SEARCHFIELD CODE /TI /AU /CS	DISPLAY FIELD CODE TI AU CS	mputer file) 9 CAPLUS COPYRIGE ull-text storage, and ice-ma & Son, London). \$4.5	emPort [®] , which gives you options allable for viewing the full text. The tions range from publisher web sites ordering the document.

Paid Vs Free databases

Derwent record	esp@cenet® record
 T1 - Protective screen for VDU, with positioning frame to restrict viewing Angle e.g. for <u>confidentiality</u> - includes transparent plate, with Louvred film to define viewing angle, fixed in frame attached Separably to VDU PNEPO599451 A1 19940601 DW199421 H01J29/89 Eng 009pp - CA2099428 A 19940411 DW199426 G02B27/02 000pp - JP6194506 A 19940715 DW199433 	NEP0599451 A 19940601 PR-IT1992TO00238U 19921001 AP -EP19930306970 19930903 EC -H01J29/89 IC -H01J29.89 IN -SOLERO GIORGIO (IT) PA -BALTEA SPA (IT) TI -Viewing angle restrictor for a visual display unit.
G025B5/004pp DC - P81 T04 DS - BE CH DE ES FR GB LINL SE AB - EP-599451 The VDU protective screen includes a transparent plate (13), and a support frame for the plate which is fixed to the VDU. The plate is a louvred film (18) which defines parallel micro- windows (22) to limit viewing angle. The frame fixing mechanism is in two separating parts, one which fixes to the frame and the other fixed to the display. The fixing mechanism uses two tabs of adhesive Velcro (RTM) Pref. the viewing angle varies as a function of the film thickness e.g. about 60deg, for a 1mm film. The frame may have front and rear half shells with corresp. Toothed projections and housings on two lateral edges, at the <u>screen</u> upper edge and opposite a seat, in the front half shell, which holds the transparent plate USE/ADVANTAGE – Portable <u>computer</u> ; prevents viewing by person outside defined limited angle. Does not form interference fringes on screen edges.	AB -A protective <u>screen</u> for a <u>visual display unit</u> (11) has a plate (13) which prevents viewing by persons other than those directly in front of the visual display unit. The plate (13) is fixed in a frame (12) to be positioned in front of the visual display unit (11) by means of tabs of adhesive velcro (27) having a first part (28) which can be fixed to the frame (12) and the second par (29) which can be fixed to the visual display unit (11). The plate (13) comprises a louvre- type film (18) which defines parallel microwindows (22) in order to define a limited viewing angle (23). 11 Jon 2013

Non-Patent/Literature Databases

- □ Scirus <u>www.scirus.com</u>
- □ Science Direct <u>www.sciencedirect.com</u>
- Delcon
- Google Scholar <u>http://scholar.google.co.in</u>
- □ STN <u>stnweb.cas.org</u>



Scirus

24

Scientific research tool on the web. With over 545 million scientific items indexed at last count, it allows researchers to search for journal content and also scientists' homepages, courseware, patents and institutional repository and website information.

SCIFUS for scientific information only				Basic search / Proferences
Advanced search				
	All of the words 🔹		in The complete document 👻	
	AND +			
	All of the words 👻		in The complete document +	
	Search tips		Search	
	author:smith DNA -sequencing car*	find results that have "smith" in the au find results that have "DNA" but not "s finds "car" as well as "carbon", etc.		
	Dates	Only show results published betwee	n,	
		before 1900 + and 2014 +		
	Information types	Only show results that are 2 Any information type Any information type Any Any information type Any information Any information Conferences	Patente Preprinta Reviews Sciential homepages Theses and Disputations	
	File Torncats	Only show results that are Any format ppr List more file types	III vrteil. III Word	
	Content sources	Only show results from		
		Pournal sources Image:	Preferred Web sources [2] all [2] E-Print ArXiv [2] Calteon [2] CogPrints [2] CogPrints [2] Curator [2] Department of Energy. 11 Jan 2013	

Science Direct





Google Scholar



Articles (include patents)
 Legal documents

Stand on the shoulders of giants



11 Jan 2013

Methodology of Search

- Keyword Search
- Patent Classification Code Search
- Chemical Structure Search
- Sequence Search



Simple Patent Search Tips

Operator	Patents				
AND	Both terms must be present				
OR	One term or the other must be present				
ΝΟΤ	NOT Term must be excluded				
ADJ	ADJ Terms should be next to each other, in the order specified				
ADJn	Terms should be within <i>n</i> words of each other, in the order specified				
NEAR	Terms should be next to each other, in any order				
NEARn	Terms should be within <i>n</i> words of each other, in any order				
SAME	Terms must be in the same paragraph, in any order				
=	Equal to (use with text as well as dates and amounts)				
<>	> Not equal to				
>	Greater than				
>=	Greater than or equal to				
<	Less than				
<=	Less than or equal to				
()	Create nests to define order of operation				
?	Stands for one character, can use multiples, can use within a term				
*	Stands for zero to many characters, can use within a term				



11 Jan 2013

Keyword Searching

- Identify keywords that relate to the fundamentals of the invention
- Use alternate terminology
- Use Generic and Specific keywords
- Use Combinations of Keywords
- Text Search in Abstract/Full Text/Claims

Invention Feature	Generic	Specific
Shape	Tube	Catheter
Material	Polymer	Polyurethane
Target Organ	Nervous Tissue	Spinal Cord
Medical Action	Heat Exchange	Cooling



Keyword Searching (contd..)

Best Searchable Field

Use Often	Abstract Often contains a collections of keyword of inventions	Assignee/ Inventor Name Active inventors, companies, continue to enrich the field	Full Text Good option for identifying IP related to your idea
Use Less Often	Title	Claims	Assignee/ Inventor Address
	For competing IP.	Patent claims have to be	Inventions may follow
	(advanced stage)	specific.	geographical pattern

Pitfalls in Keyword Searches

- English Language
- Too many Synonyms
- No Spelling Standards
- Bad Titles and Abstracts
- Innovative Lexicography
- Errors and Omissions



International Patent Classification

31

IPCs are a comprehensive subject classification system applied to all patents by the patent-issuing authorities.

authorities	5.	
	H04W 52/14	
	Section Main Class Group	
SECTION H	ELECTRICITY	
H 04	ELECTRIC COMMUNICATION TECHNIQUE	
Н 04 В	TRANSMISSION	
7/00	Radio transmission systems, i.e. using radiation fie	ld
7/185	Space-based or airborne stations	
7/19	Earth-synchronous stations	
7/195	Non-synchronous stations	
7/204	Multiple access	
7/208	Frequency-division multiple access	
7/212	Time-division multiple access	
7/216	Code-division or speed-spectrum multiple access	11 Jan 2013



Chemical Structure Search

NCBI Pub Chem

Chemspider

□ STN





Sequence Search

- NCBI BLAST
- PatentLens
- □ STN
 - GENESEQ (DGENE)

 - PCT GEN
 - CAS Registry

Program blast	1 👻 😡 🗐 Use	MegaBlast		
Database US Ar	plications nt	Di S		
Enter seque	nce below in FASTA	😺 format		
Or load it from the second	m disk		Browse_	
🖗 Or load it fro	m disk		Browse _	
Or load it fro Set subsequence		To	Browse	



34

Thank You



11 Jan 2013